To investigate whether intramyocardial injection of G-CSF-mobilized CD34+ cells is associated with greater cell retention rates and clinical improvement than an intracoronary injection of CD34+ cells, an open-label study was conducted in 40 patients with nonischemic DCM. This evidence concerns the gene CSF3 and familial dilated cardiomyopathy.